Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYSTEROXINE: Botulinum Toxin for Severe Primary Dysmenorrhea
NCT06995287Phase 3Recruiting
- Sponsor
- CHU de Nantes
- Start
- Feb 2026
- Primary completion
- Jun 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of botulinum toxin type A in primary dysmenorrhea (PD), chronic pelvic pain (CPP), sponsored by CHU de Nantes. Started Feb 2026; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
primary dysmenorrhea (PD)chronic pelvic pain (CPP)
Beyond the preview
Go deeper on NCT06995287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06995287.